Anticipated $-0.26 EPS for ConforMIS, Inc. (CFMS) as of May, 9

April 17, 2018 - By Joseph Norton

ConforMIS, Inc. (NASDAQ:CFMS) Corporate Logo

Earnings report for ConforMIS, Inc. (NASDAQ:CFMS) is awaited On May, 9., Faxor reports. Analysts predict $-0.26 EPS, which is $0.14 up or 35.00 % from 2017’s $-0.4 EPS. Wall Street now forecasts -3.70 % EPS growth despite ConforMIS, Inc. last quarter’s EPS of $-0.27. On during the last trading session the stock increased $0.01 or 0.67%, reaching $1.51.Currently ConforMIS, Inc. is downtrending after 73.56% change in last April 17, 2017. CFMS has 279,323 shares volume. CFMS underperformed by 85.11% the S&P500.

ConforMIS, Inc. (NASDAQ:CFMS) Ratings Coverage

In total 4 analysts cover ConforMIS (NASDAQ:CFMS). “Buy” rating has 3, “Sell” are 1, while 0 are “Hold”. 75% are bullish. 5 are the (NASDAQ:CFMS)’s analyst reports since December 20, 2017 according to StockzIntelligence Inc. On Tuesday, January 2 JP Morgan downgraded the shares of CFMS in report to “Underweight” rating. On Tuesday, April 10 the firm earned “Buy” rating by Canaccord Genuity. On Wednesday, December 20 BTIG Research upgraded ConforMIS, Inc. (NASDAQ:CFMS) to “Buy” rating. In Thursday, February 8 report Canaccord Genuity maintained it with “Hold” rating and $4 target.

ConforMIS, Inc., a medical technology company, develops, makes, and sells customized joint replacement implants.The firm is worth $91.87 million. The firm offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments.Last it reported negative earnings. It is also developing iTotal Hip, a customized total hip replacement implant.

ConforMIS, Inc. (NASDAQ:CFMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.